205 related articles for article (PubMed ID: 37000376)
1. Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up.
Heydemann A; Bieganski G; Wachowiak J; Czarnota J; Niezgoda A; Siemionow K; Ziemiecka A; Sikorska MH; Bozyk K; Tullius SG; Siemionow M
Stem Cell Rev Rep; 2023 Jul; 19(5):1340-1359. PubMed ID: 37000376
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of DT-DEC01 Therapy in Duchenne Muscular Dystrophy Patients: A 12 - Month Follow-Up Study After Systemic Intraosseous Administration.
Siemionow M; Biegański G; Niezgoda A; Wachowiak J; Czarnota J; Siemionow K; Ziemiecka A; Sikorska MH; Bożyk K; Heydemann A
Stem Cell Rev Rep; 2023 Nov; 19(8):2724-2740. PubMed ID: 37707670
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Motor Unit Potentials Duration as the Biomarker of DT-DEC01 Cell Therapy Efficacy in Duchenne Muscular Dystrophy Patients up to 12 Months After Systemic-Intraosseous Administration.
Niezgoda A; Biegański G; Wachowiak J; Czarnota J; Siemionow K; Heydemann A; Ziemiecka A; Sikorska MH; Bożyk K; Siemionow M
Arch Immunol Ther Exp (Warsz); 2023 Nov; 71(1):24. PubMed ID: 37999748
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.
Siemionow M; Langa P; Brodowska S; Kozlowska K; Zalants K; Budzynska K; Heydemann A
Stem Cell Rev Rep; 2022 Dec; 18(8):2872-2892. PubMed ID: 35590083
[TBL] [Abstract][Full Text] [Related]
5. Transplantation of Dystrophin Expressing Chimeric Human Cells of Myoblast/Mesenchymal Stem Cell Origin Improves Function in Duchenne Muscular Dystrophy Model.
Siemionow M; Szilagyi E; Cwykiel J; Domaszewska-Szostek A; Heydemann A; Garcia-Martinez J; Siemionow K
Stem Cells Dev; 2021 Feb; 30(4):190-202. PubMed ID: 33349121
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Biodistribution and Safety of Human Dystrophin Expressing Chimeric Cell Therapy After Systemic-Intraosseous Administration to Duchenne Muscular Dystrophy Model.
Siemionow M; Brodowska S; Langa P; Zalants K; Kozlowska K; Grau-Kazmierczak W; Heydemann A
Arch Immunol Ther Exp (Warsz); 2022 Aug; 70(1):20. PubMed ID: 35978142
[TBL] [Abstract][Full Text] [Related]
7. Human dystrophin expressing chimeric (DEC) cell therapy ameliorates cardiac, respiratory, and skeletal muscle's function in Duchenne muscular dystrophy.
Siemionow M; Langa P; Harasymczuk M; Cwykiel J; Sielewicz M; Smieszek J; Heydemann A
Stem Cells Transl Med; 2021 Oct; 10(10):1406-1418. PubMed ID: 34291884
[TBL] [Abstract][Full Text] [Related]
8. Creation of Dystrophin Expressing Chimeric Cells of Myoblast Origin as a Novel Stem Cell Based Therapy for Duchenne Muscular Dystrophy.
Siemionow M; Cwykiel J; Heydemann A; Garcia-Martinez J; Siemionow K; Szilagyi E
Stem Cell Rev Rep; 2018 Apr; 14(2):189-199. PubMed ID: 29305755
[TBL] [Abstract][Full Text] [Related]
9. Dystrophin Expressing Chimeric (DEC) Human Cells Provide a Potential Therapy for Duchenne Muscular Dystrophy.
Siemionow M; Cwykiel J; Heydemann A; Garcia J; Marchese E; Siemionow K; Szilagyi E
Stem Cell Rev Rep; 2018 Jun; 14(3):370-384. PubMed ID: 29546607
[TBL] [Abstract][Full Text] [Related]
10. Chimeric Cell Therapies as a Novel Approach for Duchenne Muscular Dystrophy (DMD) and Muscle Regeneration.
Budzynska K; Siemionow M; Stawarz K; Chambily L; Siemionow K
Biomolecules; 2024 May; 14(5):. PubMed ID: 38785982
[TBL] [Abstract][Full Text] [Related]
11. Cardiac Protection after Systemic Transplant of Dystrophin Expressing Chimeric (DEC) Cells to the mdx Mouse Model of Duchenne Muscular Dystrophy.
Siemionow M; Malik M; Langa P; Cwykiel J; Brodowska S; Heydemann A
Stem Cell Rev Rep; 2019 Dec; 15(6):827-841. PubMed ID: 31612351
[TBL] [Abstract][Full Text] [Related]
12. Amelioration of Morphological Pathology in Cardiac, Respiratory, and Skeletal Muscles Following Intraosseous Administration of Human Dystrophin Expressing Chimeric (DEC) Cells in Duchenne Muscular Dystrophy Model.
Siemionow M; Budzynska K; Zalants K; Langa P; Brodowska S; Siemionow K; Heydemann A
Biomedicines; 2024 Mar; 12(3):. PubMed ID: 38540201
[TBL] [Abstract][Full Text] [Related]
13. Intraosseous transplant of dystrophin expressing chimeric (DEC) cells improves skeletal muscle function in
Malik M; Siemionow M; Cwykiel J; Heydemann A; Garcia-Martinez J; Siemionow K; Szilagyi E
Postepy Kardiol Interwencyjnej; 2022 Dec; 18(4):399-406. PubMed ID: 36967847
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial.
Mendell JR; Sahenk Z; Lehman K; Nease C; Lowes LP; Miller NF; Iammarino MA; Alfano LN; Nicholl A; Al-Zaidy S; Lewis S; Church K; Shell R; Cripe LH; Potter RA; Griffin DA; Pozsgai E; Dugar A; Hogan M; Rodino-Klapac LR
JAMA Neurol; 2020 Sep; 77(9):1122-1131. PubMed ID: 32539076
[TBL] [Abstract][Full Text] [Related]
15. Autologous skeletal muscle derived cells expressing a novel functional dystrophin provide a potential therapy for Duchenne Muscular Dystrophy.
Meng J; Counsell JR; Reza M; Laval SH; Danos O; Thrasher A; Lochmüller H; Muntoni F; Morgan JE
Sci Rep; 2016 Jan; 6():19750. PubMed ID: 26813695
[TBL] [Abstract][Full Text] [Related]
16. Restoration of Functional Full-Length Dystrophin After Intramuscular Transplantation of Foamy Virus-Transduced Myoblasts.
Meng J; Sweeney NP; Doreste B; Muntoni F; McClure M; Morgan J
Hum Gene Ther; 2020 Feb; 31(3-4):241-252. PubMed ID: 31801386
[TBL] [Abstract][Full Text] [Related]
17. De novo revertant fiber formation and therapy testing in a 3D culture model of Duchenne muscular dystrophy skeletal muscle.
Ebrahimi M; Lad H; Fusto A; Tiper Y; Datye A; Nguyen CT; Jacques E; Moyle LA; Nguyen T; Musgrave B; Chávez-Madero C; Bigot A; Chen C; Turner S; Stewart BA; Pegoraro E; Vitiello L; Gilbert PM
Acta Biomater; 2021 Sep; 132():227-244. PubMed ID: 34048976
[TBL] [Abstract][Full Text] [Related]
18. Co-Transplantation of Bone Marrow-MSCs and Myogenic Stem/Progenitor Cells from Adult Donors Improves Muscle Function of Patients with Duchenne Muscular Dystrophy.
Klimczak A; Zimna A; Malcher A; Kozlowska U; Futoma K; Czarnota J; Kemnitz P; Bryl A; Kurpisz M
Cells; 2020 Apr; 9(5):. PubMed ID: 32365922
[TBL] [Abstract][Full Text] [Related]
19. Investigating the role of dystrophin isoform deficiency in motor function in Duchenne muscular dystrophy.
Chesshyre M; Ridout D; Hashimoto Y; Ookubo Y; Torelli S; Maresh K; Ricotti V; Abbott L; Gupta VA; Main M; Ferrari G; Kowala A; Lin YY; Tedesco FS; Scoto M; Baranello G; Manzur A; Aoki Y; Muntoni F
J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1360-1372. PubMed ID: 35083887
[TBL] [Abstract][Full Text] [Related]
20. [Therapy of Duchenne muscular dystrophy with umbilical cord blood stem cell transplantation].
Zhang C; Feng HY; Huang SL; Fang JP; Xiao LL; Yao XL; Chen C; Ye X; Zeng Y; Lu XL; Wen JM; Zhang WX; Li Z; Feng SW; Xu HG; Huang K; Zhou DH; Chen W; Xie YM; Xi J; Zhang M; Li Y; Liu Y
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Aug; 22(4):399-405. PubMed ID: 16086277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
